TAVRSTerritorial Army Volunteer Reserves (Scotland)
TAVRSThe American Veteran Radio Show
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
'This is an important contemporary snapshot of what's happening in the real world with commercial TAVR procedures,' said the study's lead author Howard C.
TAVR was approved by the Food and Drug Administration in 2011 for the treatment of aortic stenosis, a narrowing of the heart's aortic valve, and has revolutionised valve replacement options for patients with this disease who are too sick or too high risk for surgical (open-heart) valve replacement (SAVR).
Historically, PPM has been associated with worse outcomes after SAVR, however, less has been known about the incidence, outcomes, and predictors of PPM in TAVR patients.
In previous studies, severe PPM in both SAVR and TAVR patients have been associated with higher risk of death and hospital readmission, decreased exercise abilities, and a higher rate of valve deterioration over time.
TAVR may be an option for patients who are considered at risk of complications from surgical aortic valve replacement because of other conditions such as lung or kidney disease.
TAVR involves replacing damaged aortic valves with one made from cow or pig heart tissue.
The normal recovery time after a valve is replaced through open-heart surgery is four to eight weeks, but recovery after the TAVR procedure may be as short as three or four days.
The decision to treat aortic stenosis with TAVR is made after consultation with a multidisciplinary group of medical and surgical heart specialists who determine together the best treatment option for each individual.
In the clinical study to evaluate safety and effectiveness that Morton Plant Hospital participated in, 1,011 aortic stenosis patients at intermediate risk for standard aortic valve replacement with open heart surgery were randomly selected to have the TAVR procedure using the Sapien XT valve and 1,021 were randomly selected to have a traditional aortic valve replacement with a surgical tissue valve utilizing open-heart surgery.
Two major factors eventually drove the decision to proceed: FDA approval of the TAVR procedure and the hybrid OR's potential for improved patient care.
Demand for the room's capabilities is so strong from vascular, gynecological, interventional radiology, TAVR, aortic/thoracic, and electrophysiological surgeons that a second hybrid OR is under consideration at the facility.
John Messenger, UCH director of cardiac catheter labs and TAVR surgeon.